

Particle Dispersion Devices – Addressing B12 Deficiency

ROONTECH LTD

The Problem: Millions of people are B12 deficient, and many cannot absorb via the stomach and require injections. Predominantly medical professionals carry out procedures every 8- 12 weeks, however, boosts can decline at just 6 weeks leaving patients feeling fatigued with headaches, or worse, irreversible decline. Many are self-medicating or using Beauticians and Vapes as they believe the healthcare system does not fulfil their requirements, this is dangerous on all fronts.

Our Solution: A non-invasive, home-use device that delivers B12 and other nutrients as airborne particles, absorbed via the lungs. No needles, no clinics—just consistent, convenient relief.

How It Works: After an initial blood test identifies deficiencies, pre-dosed canisters connect to a user-friendly inhaler or dispersion unit, like an air mister. Safe, precise, and tailored to individual needs.

The Impact:

- **Patients:** Fewer symptoms, better health, and autonomy from home.
- **Healthcare:** Reduced strain on systems like the NHS, cutting injection-related costs.
- **Market:** A scalable platform for nutrient delivery, tapping into the £1.5B at-home health tech boom.

Why ROONTECH? Our team combines electrical and mechanical expertise with MSc-level research into nanoparticle lung delivery, inspired by personal experience with B12 deficiency. Unlike risky “B12 vapes,” which are harmful to Lungs causing breathing difficulties, our method prioritizes safety and efficacy by utilising hydrofluoroalkane (HFA) propellants, unlocking a gap professionals have yet to address.

Cost: “The Inhaler using existing tech costs £10”. Cannisters and Dispersion unit costs are to be determined pending prototype refinement. However, by offsetting NHS appointments of £30 per visit a cost-effective solution is evident.

Funding Need: £500K for prototype development, clinical trials, and expert collaboration to validate lung-based delivery. Goal: A market-ready product in 18 months.

Opportunity: Investors gain equity, ROI potential, or buyout options in a first-mover solution.

Interested?

Contact us at www.roontech.co.uk/contact

